Affordable Access

Cost analysis of drug therapy in rheumatoid arthritis

Revista Brasileira de Ci?ncias Farmac?uticas
Publication Date
  • Rheumatoid Arthritis/Drug Therapy
  • Dmards
  • Anti-Tnf
  • Pharmacoeconomy Analysis
  • Medicine


With the aim to compare the cost of treatment for rheumatoid arthritis therapy with desease-modifying antirheumatic drugs (DMARDS) for a 48-month period, were studied five different treatment stage based on clinical protocols recommended by the Brazilian Society of Rheumatology, and then five therapy cycles. The analytical model based on the Markov Analysis, considered chaces for the patient continue in some stages or change between them according with a positive effect on outcomes. Only direct costs were comprised in the analyzed data, like drugs, materials and tests used for monitoring these patients. The results of the model show that the stage in with metotrexato drug is used like monotherapy was cost-effective (R$ 113,900,00 for patient during 48 months), followed by refractory patient (R$ 1,554,483,43), those that use therapy triplicate followed by infleximable drug (R$ 1, 701, 286.76), the metotrexato intolearant patient (R$ 2,629,919,14), and final the result from that use metotrexato and infliximable in the beginning (R$ 9,292,879,31). The sensitivity analysis confirm this results, when alternate the efficacy of metotrexato and infliximabe.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

The total costs of drug therapy for rheumatoid art...

on Arthritis & Rheumatism March 1995

The total cost of drug therapy for rheumatoid arth...

on Arthritis & Rheumatism December 1995

Cost effectiveness analysis of drug therapies for...

on The Journal of rheumatology. S... March 1996

Biologic drugs for rheumatoid arthritis in the Med...

on Arthritis & Rheumatism April 2008
More articles like this..